CEACAM5 and cancer: As much as 26 of 28 N-glycosylation sites were identified in plasma with 500 ng/ml CEA spiked in, and site-specific glycosylation of CEA could be profiled in plasma samples of individual cancer patients with concentration as low as 1 ng/ml.